These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 34488413)

  • 1. Response of autoimmune and inflammatory disorders in myelodysplastic syndromes to 5-azacytidine: report of two cases and literature review.
    Wu DY; Wang J; Zhang R; Yan XJ; Gao R
    Ann Palliat Med; 2021 Aug; 10(8):9276-9280. PubMed ID: 34488413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Azacitidine-associated Sweet's syndrome.
    Trickett HB; Cumpston A; Craig M
    Am J Health Syst Pharm; 2012 May; 69(10):869-71. PubMed ID: 22555082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complete remission of Sweet's syndrome after azacytidine treatment for concomitant myelodysplastic syndrome.
    Martinelli S; Rigolin GM; Leo G; Gafà R; Lista E; Cibien F; Sofritti O; Daghia G; Cavazzini F; Cuneo A
    Int J Hematol; 2014; 99(5):663-7. PubMed ID: 24554168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histiocytoid Sweet's syndrome potentially related to decitabine in a patient with myelodysplastic syndrome.
    Park JY; Park JS; Kim YC
    Eur J Dermatol; 2012; 22(6):811-2. PubMed ID: 23178879
    [No Abstract]   [Full Text] [Related]  

  • 5. Paraneoplastic inflammation in myelodysplastic syndrome or bone marrow failure: case series with focus on 5-azacytidine and literature review.
    Frietsch JJ; Dornaus S; Neumann T; Scholl S; Schmidt V; Kunert C; Sayer HG; Hochhaus A; La Rosée P
    Eur J Haematol; 2014 Sep; 93(3):247-59. PubMed ID: 24635656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atypical presentations of Sweet's syndrome in patients with MDS/AML receiving combinations of hypomethylating agents with histone deacetylase inhibitors.
    Alencar C; Abramowtiz M; Parekh S; Braunshweig I; Jacobson M; Silverman L; Verma A
    Am J Hematol; 2009 Oct; 84(10):688-9. PubMed ID: 19722261
    [No Abstract]   [Full Text] [Related]  

  • 7. [Sweet's syndrome induced by pegfilgrastim during a myelodysplastic syndrome AREB2: A case report].
    Nelis S; Azerad MA; Drowart A; Lewalle P; Efira A
    Rev Med Interne; 2019 Apr; 40(4):258-261. PubMed ID: 30551891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A case of polycyclic Sweet's syndrome arising from azacitidine injection sites in myelodysplasia.
    Berry WA; Kelly R
    Ann Hematol; 2020 Jan; 99(1):201-202. PubMed ID: 31820051
    [No Abstract]   [Full Text] [Related]  

  • 9. Sweet's syndrome associated with hematological malignancies.
    Maller B; Bigness A; Moiño D; Greene J
    Leuk Res; 2020 Dec; 99():106461. PubMed ID: 33099235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Normolipemic xanthomatized Sweet's syndrome: A variant of Sweet's syndrome with myelodysplastic syndrome.
    Kamimura A; Yanagisawa H; Tsunemi Y; Kusano T; Arai E; Tsuchida T; Nakamura K
    J Dermatol; 2021 May; 48(5):695-698. PubMed ID: 33580905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inflammatory disorders associated with trisomy 8-myelodysplastic syndromes: French retrospective case-control study.
    Wesner N; Drevon L; Guedon A; Fraison JB; Trad S; Kahn JE; Aouba A; Gillard J; Ponsoye M; Hanslik T; Gourguechon C; Liozon E; Laribi K; Rossignol J; Hermine O; Adès L; Carrat F; Fenaux P; Mekinian A; Fain O;
    Eur J Haematol; 2019 Jan; 102(1):63-69. PubMed ID: 30218579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Successful treatment of an essential thrombocythemia patient complicated by Sweet's syndrome with combination of chemotherapy and lenalidomide].
    Yamada M; Kuroda H; Yoshida M; Jomen W; Abe T; Sakurai T; Fujii S; Maeda M; Fujita M; Nagashima K; Matsuno T; Sato M; Kato J
    Rinsho Ketsueki; 2014 Apr; 55(4):440-4. PubMed ID: 24850455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sweet's syndrome evolved from recurrent erythema nodosum in a patient with myelodysplastic syndrome.
    Nishie W; Kimura T; Kanagawa M
    J Dermatol; 2002 Feb; 29(2):91-5. PubMed ID: 11890302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Myelodysplastic syndrome with Sweet's syndrome--one case report and literature review].
    Zhang F; Lin Y; Li J
    Zhonghua Xue Ye Xue Za Zhi; 1999 Jul; 20(7):369-70. PubMed ID: 11721436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cryptogenic organizing pneumonia in Sweet's syndrome: case report and review of the literature.
    Tzelepis E; Kampolis CF; Vlachadami I; Moschovi M; Alamani M; Kaltsas G
    Clin Respir J; 2016 Mar; 10(2):250-4. PubMed ID: 25196175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low dose IL-2 in patients with steroid-dependent dysimmune manifestations associated with myelodysplastic syndromes: a three-case report.
    Corfmat M; Willekens C; Vinit J; Bussone G; Fenaux P; Fain O; Klatzmann D; Mekinian A; Comont T;
    Rheumatology (Oxford); 2021 Jul; 60(7):3404-3408. PubMed ID: 33164099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful azacitidine therapy for myelodysplastic syndrome associated with VEXAS syndrome.
    Kataoka A; Mizumoto C; Kanda J; Iwasaki M; Sakurada M; Oka T; Fujimoto M; Yamamoto Y; Yamashita K; Nannya Y; Ogawa S; Takaori-Kondo A
    Int J Hematol; 2023 Jun; 117(6):919-924. PubMed ID: 36641501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiretroviral activity of 5-azacytidine during treatment of a HTLV-1 positive myelodysplastic syndrome with autoimmune manifestations.
    Diamantopoulos PT; Michael M; Benopoulou O; Bazanis E; Tzeletas G; Meletis J; Vayopoulos G; Viniou NA
    Virol J; 2012 Jan; 9():1. PubMed ID: 22214262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Appearance of Sweet's syndrome in a patient with myelodysplastic syndrome (MDS) without relation to the hematological findings of MDS].
    Hasegawa Y; Tomiyama J; Ninomiya H; Abe T
    Rinsho Ketsueki; 1989 Jun; 30(6):863-7. PubMed ID: 2795896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lymphocytic infiltrates as a presenting feature of Sweet's syndrome with myelodysplasia and response to cyclophosphamide.
    Evans AV; Sabroe RA; Liddell K; Russell-Jones R
    Br J Dermatol; 2002 Jun; 146(6):1087-90. PubMed ID: 12072085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.